Gamida Cell Ltd’s (GMDA) Quiet Period To Expire Tomorrow

Gamida Cell’s (NASDAQ:GMDA) quiet period is set to end on Wednesday, December 5th. Gamida Cell had issued 6,250,000 shares in its public offering on October 26th. The total size of the offering was $50,000,000 based on an initial share price of $8.00. During the company’s quiet period, insiders and any underwriters that worked on the IPO are restricted from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

Several research analysts have weighed in on GMDA shares. Royal Bank of Canada started coverage on shares of Gamida Cell in a research report on Tuesday, November 20th. They issued an “outperform” rating and a $20.00 price target on the stock. BMO Capital Markets started coverage on shares of Gamida Cell in a research report on Wednesday, November 21st. They issued a “buy” rating and a $19.00 price target on the stock. Oppenheimer started coverage on shares of Gamida Cell in a research report on Wednesday, November 21st. They issued an “outperform” rating and a $15.00 price target on the stock. CIBC started coverage on shares of Gamida Cell in a research report on Wednesday, November 21st. They issued an “outperform” rating and a $15.00 price target on the stock. Finally, Needham & Company LLC started coverage on shares of Gamida Cell in a research report on Monday, November 26th. They issued a “buy” rating and a $23.00 price target on the stock. Five equities research analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and an average price target of $18.40.

GMDA opened at $13.81 on Tuesday. Gamida Cell has a 1-year low of $7.99 and a 1-year high of $15.41.

ILLEGAL ACTIVITY NOTICE: “Gamida Cell Ltd’s (GMDA) Quiet Period To Expire Tomorrow” was reported by Community Financial News and is owned by of Community Financial News. If you are reading this article on another website, it was illegally copied and republished in violation of international copyright and trademark laws. The original version of this article can be viewed at https://www.com-unik.info/2018/12/04/gamida-cell-ltds-gmda-quiet-period-to-expire-tomorrow.html.

About Gamida Cell

Gamida Cell Ltd., a clinical stage biopharmaceutical company, focuses on developing cell therapies to cure cancer, and rare and serious hematologic diseases in the United States, the European Union, and internationally. The company's lead product candidate is NiCord, a nicotinamide (NAM)-expanded cord blood cell therapy that is in Phase 3 clinical trials for use as a curative stem cell graft for patients in hematopoietic stem cell transplant.

Recommended Story: Why is the Consumer Price Index (CPI) important?

Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit